«This is an important step in immunotherapy research for multiple myeloma, a tough - to - beat cancer that is largely incurable, with a five - year survival rate of approximately 50 percent — highlighting the need for new approaches to improve therapeutic options including after an ASCT,» said Edward Stadtmauer, MD, a professor of Medicine and section chief of Hematologic Malignancies in the ACC, and co-lead author. (sciencedaily.com)
We also evaluate and treat patients with hematologic diseases such as immune - mediated anemia, immune - mediated thrombocytopenia, and bone marrow disorders. (vet.osu.edu)
Is post-transplant cyclophosphamide — based haploidentical donor transplantation appropriate for racial and ethnic minority patients with hematologic cancers? (cancernetwork.com)